tagrisso
astrazeneca ab - osimertinib mesilate - carcinoma, pulmón no microcítico - otros agentes antineoplásicos, inhibidores de la proteína quinasa - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.
osimertinib comprimidos recubiertos 40 mg
alembic pharmaceuticals s.p.a. - osimertinib - sin formulas
osimertinib comprimidos recubiertos 80 mg
alembic pharmaceuticals s.p.a. - osimertinib - sin formulas
tagrisso comprimidos recubiertos 40 mg (osimertinib)
astrazeneca s.a. - osimertinib - sin formulas
tagrisso comprimidos recubiertos 80 mg (osimertinib)
astrazeneca s.a. - osimertinib - sin formulas
tagrisso 80 mg
astrazeneca ab, sÖdertÄlje, suecia - osimertinib - comprimido recubierto - 80 mg
tagrisso 40 mg
astrazeneca ab, sÖdertÄlje, suecia - osimertinib - comprimido recubierto - 40 mg
tagrisso® 40 mg
astrazeneca ab. - osimertinib (eq. a 47,7 mg de mesilato de osimertinib) - comprimido recubierto - 40 mg
tagrisso® 80 mg
astrazeneca ab. - osimertinib (eq. a 95,4 mg de mesilato de osimertinib) - comprimido recubierto - 80 mg
tagrisso 80 mg comprimidos recubiertos con película
astrazeneca ab suecia - osimertinib 80 mg - comprimido recubierto con pelicula - cada comprimido recubierto con película contiene: osimertinib mesilato 95.4 mg equivalente a 80 mg de osimertinib